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Patients with human immunodeﬁciency virus/acquired immune deﬁciency syndrome (HIV/AIDS) are at increased risk for
developing Hodgkin’s lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy
(cART) in the modern era. HIV-associated HL (HIV-HL) diﬀers from HL in non-HIV-infected patients in that it is nearly
always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic
“B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and
worseoutcomesthannon-HIV-infectedHLpatientstreatedwithconventionalchemotherapy.TheintroductionofcART,however,
has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those
seen in non-HIV infected patients. Despite these signiﬁcant advances, HIV-HL patients remain at increased risk for treatment-
related toxicities and drug-drug interactions which require careful attention and supportive care to insure the safe administration
of therapy. This paper will address the modern diagnosis, risk stratiﬁcation, and therapy of HIV-associated HL.
1.Introduction
Since the introduction of combination antiretroviral therapy
(cART) in 1996, patients with human immunodeﬁciency
virus (HIV) infection are living longer, with improved
immune function and a reduced risk of developing acquired
immune deﬁciency syndrome (AIDS) [1, 2]. In concert with
improved viral control, there has been a substantial change
in the landscape of malignancies occurring in the setting
of HIV. AIDS-deﬁning cancers such as Kaposi’s sarcoma
(KS) and non-Hodgkin’s lymphomas (NHL) have declined
signiﬁcantly, though the change in NHL incidence has not
applied evenly across disease subtypes. Diﬀuse large B-cell
lymphoma, primary CNS lymphoma, plasmablastic lym-
phoma, and primary eﬀusion lymphoma have all declined,
while Burkitt lymphoma has remained stable. Over the same
time period, non-AIDS-deﬁning malignancies, including
numerous solid tumors and Hodgkin’s lymphoma (HL),
have remained stable or have increased in incidence [3, 4].
ThegrowthofanagingpopulationwithHIVhascontributed
to this rise, but the risk of many of these cancers remains
signiﬁcantly increased above that observed in the general
population, suggesting an eﬀect of ongoing virus-mediated
immune suppression and stimulation on cancer risk despite
the salutary eﬀects of antiretroviral therapy [3–8].
There will be approximately 8800 new cases of HL
diagnosed this year in the United States and 1300 deaths [9].
HL outside of HIV is a disease characterized by a bimodal
age distribution with an initial peak at age 20–30 and a
second peak at age 50–65 [10], while the median age of HL
presentation in HIV is in the 30s [11]. The incidence of this
disease in HIV-positive patients is 5–10 times higher than
in the general population, and may be increasing since
the introduction of cART [3–8, 12, 13]. Histologically, the
malignant Hodgkin Reed-Sternberg (HRS) cells comprise
less than 1% of the tumor cellularity, with the majority made
upofsurroundingpolyclonallymphocytes,eosinophils,neu-
trophils,macrophages,plasmacells,ﬁbroblasts,andcollagen.
The HRS cell interacts with its microenvironment via cell-
cell contact and elaboration of growth factors and cytokines,2 Advances in Hematology
which results in a surrounding cellular milieu that protects it
from host immune attack. The surrounding environmental
cells likewise support the HRS cells via cell-cell signaling and
cytokine production which provides the necessary signals
that promote proliferation and survival of the HRS cell
itself.Severeimmunosuppression,asinadvancedHIV/AIDS,
may disrupt this productive relationship with the host
microenvironment, resulting in a decreased incidence of HL
in the setting of profound immunosuppression. This may
explain why the incidence of HL in HIV peaks at a modestly
decreased CD4 count (150–199cells/µL), and disease risk
is associated with cART, but it is rarely seen at severely
depressed CD4 counts [4, 14, 15]. While the introduction of
cARThasnotresultedinadecreasedincidenceofthisdisease,
it has resulted in signiﬁcantly improved outcomes following
treatment,resultinglargelyfromdecreasedtreatment-related
morbidity and mortality, the ability to treat with full-
dose chemotherapy regimens, and an increasing incidence
of lower-risk disease. As such, patients with HIV-HL now
enjoy similar response rates and progression-free and overall
survivals to their stage- and risk-matched non-HIV infected
counterparts.
2. Epidemiology and Pathology
The epidemiologic and pathologic pattern of HIV-associated
HL is distinct from that observed in HIV-negative patients.
There is an increased risk of developing HL in HIV-infected
patients compared to the general population, and this risk
remains increased since the advent of cART [3–8, 12, 13].
In a prospective cohort of 11,112 HIV-positive patients,
the incidence of HL was nearly 14 times higher than that
of the general population, with variation based on the era
of diagnosis; standardized incidence was 4.5 times higher
than the general population in the pre-cART era (1983–
1985) compared to 32 times higher in the cART era (2002–
2007) [4]. These observations were replicated in the Swiss
HIV Cohort Study of 9429 HIV-infected patients, where HL
standardized incidence was 9 times increased in the pre-
cART era, compared with 21 times increased in the early
cART era and 28 times increased in the late cART era [7].
This is consistent with multivariate analysis revealing that
cART and speciﬁcally nonnucleoside reverse transcriptase
inhibitors are associated with an increased risk of developing
HIV-HL [4]. In addition, the pattern of histologic subtypes
of HL seen in HIV-infected patients diﬀers from the general
population, with a greater proportion of mixed cellularity
(MC) and lymphocyte depletion (LD) observed in the
former [16, 17]. MC and LD subtypes of classical HL are
correlated with more advanced immune compromise, while
nodular sclerosis (NS) histology increases with higher CD4
counts and use of cART [15].
Viral oncogenesis appears to play a greater role in HIV-
HL than HL in the general population. Epstein-Barr virus
(EBV) can be detected in approximately one-third of cases
of non-HIV-associated HL, compared to nearly all cases of
HIV-HL [11, 15]. HRS cells in HIV-HL express the EBV-
transforming protein latent membrane protein 1 (LMP-1),
and the EBV genomes from multiple disease sites in the same
HIV-HLpatientareepisomalandclonal,suggestingthatEBV
is directly involved in lymphomagenesis [18–21].
3. ClinicalPresentationandPrognostic Factors
HIV-HL in the modern era presents at a median age in
the mid 30s after a median time from HIV diagnosis of
approximately 7 1/2 years. Approximately one quarter of
patients will have a prior AIDS diagnosis at the time their
cancer is diagnosed, and the majority of patients will be
diagnosed while receiving cART. The median CD4 count
at HL diagnosis is approximately 240cells/µL. The most
common histology is MC in approximately half of patients,
followedbyNSinonequarterandLDinapproximately10%.
Representative pathologic images are shown in Figure 1.T h e
majority of patients present with advanced-stage disease
(Ann Arbor stage III-IV), though the incidence of early-
stage disease appears to be increasing in the cART era.
The majority of patients still present with systemic “B”
symptoms, and extranodal involvement remains common
[11, 17, 22–24].
Prior to the availability of cART, prognosis of HIV-
HL was poor with very few patients cured of their disease.
A number of adverse prognostic factors were identiﬁed,
including MC subtype, extranodal involvement, presence of
systemic “B” symptoms, and a high International Prognostic
Score (IPS) [11, 25]. The development of cART has signiﬁ-
cantly changed the natural history and risk stratiﬁcation of
HIV-HL. The Spanish GESIDA group compared 83 patients
with HIV-HL treated with cART to 21 patients with HIV-
HL not treated with cART and found similarly high-risk
clinical characteristics in the two groups at baseline but
with signiﬁcantly better outcome in patients receiving cART,
includingahighercompleteremission(CR)rate(91%versus
70%) and longer median OS longer (not reached versus
39 months) [26]. A CD4 count >100/µL and use of cART
were independently associated with a favorable outcome.
Other studies have documented the importance of cART on
prognosis with improved responses to chemotherapy and
survival in the cART era [27, 28]. Importantly, it appears
that responding to cART is signiﬁcant as patients who fail
to respond to cART have similarly poor outcomes as patients
in the pre-cART era [28].
4.InitialStagingandEvaluation
Regardless of an underlying HIV diagnosis, all patients with
newlydiagnosedHLrequireacarefulmedicalhistoryinclud-
ing questions regarding systemic “B” symptoms, and a phys-
ical exam with attention paid to both nodal and extranodal
sites. Laboratory evaluation should include a complete blood
c o u n tw i t hd i ﬀerential, erythrocyte sedimentation rate, and
chemistry tests including a complete metabolic panel with
liver function tests and albumin. Baseline HIV parameters
including CD4 count and viral load should be tested, along
with hepatitis B and C serologies given risk of coinfec-
tion. Patients with any HIV-associated malignancy may
present with concurrent opportunistic infections or otherAdvances in Hematology 3
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Figure 1: Representative images of mixed cellularity HIV-associated classical Hodgkin’s lymphoma. (a) High-power H and E image shows
a prominent Hodgkin Reed Sternberg (HRS) cell surrounded by a mixed population of lymphocytes, eosinophils, granulocytes, and
histiocytes. (b) Low-power view of CD30 immunohistochemistry highlights the rare large HRS cells, as does in-situ hybridization for EBER
(c), reﬂecting the Epstein-Barr virus (EBV) infection of HRS cells.
HIV-associated malignancies, so any ﬁndings not readily
ascribed to the HL should be evaluated further as clinically
indicated.
Initial radiographic staging is increasingly with Positron
Emission Tomography/Computed Tomography (PET/CT)
scans, which are associated with a higher sensitivity, speci-
ﬁcity, and positive and negative predictive value than tra-
ditional CT scans in the initial staging of HL [29]. They
may also be useful in evaluating for bone marrow involve-
ment, which is often patchy in HL, though false positives
do occur [30]. The value of PET/CT scans for staging
speciﬁcally in patients with HIV-associated HL has not
been studied and is less clear than that in the non-HIV-
infected patients due to a higher rate of false positives
owing to the competing infectious, inﬂammatory, and/or
malignant processes that may produce PET-avid lesions
in immunosuppressed patients. PET certainly adds to the
sensitivity in detecting extranodal sites of disease, which
are present in the majority of patients with HIV-HL and
may be missed on conventional CT scanning. Bone marrow
aspiration and biopsy should generally be performed at
diagnosisandrepeatedfollowingtherapyforconﬁrmationof
CR only if positive at presentation. Patients with HIV/AIDS
are at increased risk for cardiovascular and pulmonary
disease of multiple etiologies, and these organs may also be
injured by chemotherapy; as a result, all patients should have
a pre-treatment assessment of cardiac function (echocar-
diogram or multigated acquisition scan) and pulmonary
function tests, given the risks associated with doxorubicin
and bleomycin, respectively.
5. InitialTreatment
The most commonly used initial systemic therapy for HL
worldwide is the combination of doxorubicin, bleomycin,
vinblastine, and dacarbazine (ABVD). When ABVD was
given to patients with HIV-HL in the pre-cART era, the
objective response rate was a disappointing 62% with a
median OS of only 1.5 years [31]. Even though the majority
of these patients had high-risk features at diagnosis includ-
ing stage IV disease, bone marrow involvement, and “B”
symptoms, these results are markedly inferior to outcomes
expected in high-risk patients with HL not associated
with HIV. Despite all patients receiving granulocyte-colony-
stimulating factor (G-CSF), over half of these patients expe-
rienced signiﬁcant neutropenia requiring treatment delays,
and the incidence of opportunistic infections, despite pro-
phylactic antimicrobials, was 29%, with the same percentage
of patients experiencing fatal infections during the study
period. A slightly higher response rate but shorter OS was
observed when epirubicin, bleomycin, and vinblastine were
given to HIV-HL patients before the introduction of cART,
but most of the responders were patients with a better
performance status and without a history of opportunistic4 Advances in Hematology
Table 1: Prospective studies of combination chemotherapy for HIV-HL in the cART era.
Regimen N Initial CD4 Count/µL, Advanced stage Extranodal disease “B” symptoms Response rate Overall survival
EBV [32] 17 184 88% 77% 82% 82% 48% (36m)
EBVP [33] 35 219 83% 84% 89% 91% 32% (36m)
ABVD [34] 62 129 100% N/R 89% 87% 76% (60m)
Stanford V [35] 59 238 71% 47% 75% 89% 51% (36m)
BEACOPP [36] 12 205 92% 42% 83% 100% 75% (36m)
VEBEP [37] 71 248 70% NR NR 79% 69% (48m)
EBV: epirubicin, bleomycin, vinblastine; EBVP: epirubicin, bleomycin, vinblastine, prednisone; ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine;
BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; VEBEP: vinorelbine, epirubicin, bleomycin,
cyclophosphamide, prednisone; NR: not reported.
infections [32]. Decreased response rates, due to dose
reductions and delays, higher risk disease, and increased
treatment-related morbidity and mortality all contribute to
the inferior outcomes during this era.
The introduction of cART and its associated improved
control of HIV infection, immune status, and performance
status have allowed for administration of full-dose-intensive
regimens with improved outcomes (Table 1). In the early
cART era, the treatment of 35 patients with advanced high-
risk HIV-HL with EBV plus prednisone (EBVP) and either
zidovudine or dideoxyinosine resulted in an overall response
rate of 91%, but still with a disappointing median overall
survival of 16 months and a 3-year OS and DFS of 32%
and 53%, respectively [33], highlighting an ongoing high
rate of nonrelapse mortality. The delivery of chemotherapy
with cART proved feasible, however, and demonstrated an
increased ability to cure HL in a subset of these very high-
risk patients.
As cART has evolved, treatment results in HIV-HL
have further improved. A prospective phase 2 study of the
Stanford V regimen with cART in 59 patients with HIV-HL
found that less than one-third of patients required a dose
reduction or delay [35].Thesepatientshadbetterriskdisease
than those reported previously, with a greater proportion
of patients with a good performance status and early-stage
disease, and fewer patients with extranodal involvement and
“B” symptoms. The median pre-treatment CD4 count was
238 cells/µL. Eighty-one percent of patients achieved a CR,
with a 5-year OS and DFS of 59% and 68%, respectively. An
IPS <2 was associated with improved freedom from progres-
sion. The more intensive regimen of bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine,
and prednisone (BEACOPP) similarly resulted in a high rate
of CR in all 12 HIV-HL patients in a small report [36].
Two-thirds of these patients had a good performance status
and the median CD4 count was 205/µL, but there was a
greaterproportionofadvanced-stagedisease,“B”symptoms,
and extranodal involvement than that in the European
Intergroup study of Stanford V. After 4 years, there had only
beenonerelapse,buttheincidenceofsevereneutropeniawas
75%, and two patients died from opportunistic infections.
ABVD was reexamined in conjunction with cART in
a cohort of 62 high-risk HIV-HL patients, 87% of whom
achieved a CR, with an encouraging 5-year OS and event-
free survival (EFS) of 76% and 71%, respectively [34].
An immunologic response to cART was associated with
improved outcome. Finally, GICAT explored the use of
epirubicin, bleomycin, vinorelbine, cyclophosphamide, and
prednisone (VEBEP) in 71 patients with HIV-HL, many of
whom had advanced-stage and high-risk disease by IPS [37].
The CR rate was 67%, with 69% of patients alive and 86% of
patients disease-free at 2 years.
As noted earlier, the introduction of cART has resulted
in an increased number of HIV-HL patients presenting
with earlier-stage disease. The optimum therapy for early-
stage HL is controversial and an area of active investiga-
tion. Combined modality therapy with chemotherapy and
radiation has been the standard of care, but late compli-
cations of radiotherapy including secondary malignancies
and heart and lung disease have prompted consideration of
chemotherapy alone in selected patients. Randomized trials
in nonbulky limited-stage disease have identiﬁed no survival
beneﬁt favoring inclusion of radiotherapy, and retrospective
analyses of chemotherapy alone show encouraging results,
so avoiding radiotherapy is an option for limited stage
patients without presenting bulk, with the caveat that HIV-
HL patients have not been included in these studies [45–47].
Although this has not been studied in patients with early-
stage HIV-HL, it is reasonable to approach the treatment of
early stage HIV-HL similarly to that of HL patients without
concomitant HIV infection, with appropriate attention to
supportive care.
These data demonstrate that HIV-HL patients treated
with concurrent cART in the modern era achieve similarly
encouraging results as those seen in the general population
when disease risk factors are matched. The improved out-
comes in patients with HIV-HL demonstrate the importance
of improved immunologic status and performance status,
and the ability to treat on schedule and at full dose intensity
in the modern era.
6. Relapsed andRefractory Disease
Despite improved outcomes with initial therapy, a number
of HIV-HL patients still relapse, for whom prognosis is poor.
High-dose chemotherapy with autologous stem cell trans-
plantation (HDC-ASCT) remains the standard of care in
HIV-negative patients with relapsed HL based on improved
PFS and EFS compared to traditional salvage chemotherapy
[48, 49]. In the cART era, HDC-ASCT has been shown to beAdvances in Hematology 5
Table 2: Studies of high-dose chemotherapy with autologous stem cell transplantation in relapsed HIV-associated lymphomas.
Study N %HL cART Complete response Disease-free survival Overall survival Treatment-related
mortality
Gabarre et al. [38] 14 43% Yes 71% 29% (26m) 36% (32m) 0%
Krishnan et al. [39] 20 10% Yes 90% 85% (32m) 85% (32m) 5%
Serrano et al. [40] 14 21% Yes 73% 65% (30m) 65% (30m) 0%
Spitzer et al. [41] 20 25% Yes 53% 49% (6m) 74% (6m) 5%
Balsalobre et al. [42] 68 26% Yes NR 56% (32m) 61% (32m) 4%
Re et al. [43] 50




D´ ıez-Mart´ ın et al. [44] 53 34% Yes NR 61% (30m) 62% (30m) NR
NR: not reported.
∗Indicates results for only patients who received high-dose chemotherapy followed by autologous stem cell transplantation.
a feasible and successful strategy in relapsed or refractory
HIV-HL as well, but with signiﬁcant potential toxicity [38–
44, 50]( Table 2). A prospective study of HDC-ASCT as
salvage therapy for AIDS-related lymphomas included 50
patients, 24 of whom actually received the planned HDC-
ASCT [50]. The median OS for the entire cohort was
only 7 months, but the median OS for patients undergo-
ing transplantation had not been reached at 44 months,
demonstrating that a favorable outcome can be achieved
in selected cases of relapsed HIV-HL. These ﬁndings are
supported by a retrospective analysis of HDC-ASCT in
relapsed HIV-associated lymphoma patients (one-third of
whom had HL), where PFS and OS were similar to an
HIV-negative cohort matched for disease risk factors [44].
The incidence of grade 3 and 4 toxicities following HDC-
ASCT for HIV-HL is approximately 30–40%, including
upper and lower gastrointestinal toxicity, hepatotoxicity, and
neutropenic infections [38–44, 50]. In addition, the rate
of viral reactivation and infections with cytomegalovirus,
herpes zoster virus, and/or varicella zoster virus is 10–25%,
and 5–7% for fungal infections; these are similar to that
observed following HDC-ASCT in non-HIV patients [38–
44, 50, 51]. The rate of transplant-related mortality is also
comparable to that seen following autologous transplanta-
tion in patients not infected with HIV and ranges from 0
to 5% across available studies [38–44, 50]. For appropriately
selected patients, HDC-ASCT is feasible and eﬀective salvage
therapy for relapsed or refractory HIV-HL, but this should
only be performed at transplant centers experienced in the
administration of high-dose chemotherapy to HIV-infected
individuals.
The data exploring the use of allogeneic stem cell
transplant are retrospective or based on case reports. The
Center for International Blood and Marrow Transplantation
Research reported the experience of 27 HIV-associated lym-
phoma patients treated with allogeneic transplantation from
1986 to 2003 [52]. Two-year OS was only 22% in this group,
although survival was improved in the post- compared with
pre-cART era. Given the limited experience and high-risks
of this approach, allogeneic stem cell transplantation should
be considered experimental and optimally performed in the
setting of a clinical trial.
For patients who are not candidates for, or who have
relapsed after, HDC-ASCT, traditional chemotherapy agents
remain available as monotherapy or in combination. While
these therapies may induce remissions, this is without sig-
niﬁcant opportunity for cure and is associated with ongoing
chemotherapy toxicities and immune suppression. Novel
agents are now becoming available for relapsed/refractory
HL,thoughtheyhavenotbeenstudiedtodateintheHIV-HL
population. Brentuximab vedotin (SGN-35) is a monoclonal
antibody against CD30 that is bound to the microtubule
toxin monomethyl auristatin E (MMAE) and has recently
beenFDAapprovedforthetreatmentofHodgkinlymphoma
that has relapsed after HDC-ASCT, or in patients ineligible
for ASCT. In non-HIV-infected HL patients, all of whom
had failed prior HDC-ASCT, the overall response rate was a
remarkable 75% with 34% of patients achieving a CR, many
of which appeared durable [53]. This novel targeted therapy
emerges as an appealing chemotherapy-sparing treatment
option for relapsed HIV-HL patients who have relapsed
after, or are not candidates for, high-dose chemotherapy.
Additionalnovelagentsarecurrentlyunderinvestigationand
appear promising in HL, including mTOR inhibitors and
histone deacetylase inhibitors, among others.
7.RestagingandFollow-Up
Following completion of therapy, restaging with PET/CT
scans in non-HIV-infected HL patients is better at diﬀer-
entiating between viable and necrotic/ﬁbrotic tumor than
traditional CT scans and has a higher positive and negative
predictive value [54]. In addition, an interim PET/CT
response after 2-3 cycles of chemotherapy carries signiﬁcant
prognostic value in this disease, although patients who
convert to PET negative at the end of therapy have been
shown to do similarly well to those who are PET negative
mid-therapy [55–58] .T h e r ei sn oe v i d e n c et od a t e ,h o w e v e r ,
that interim PET/CT results can be used to alter treatment
plans, and this is being evaluated in a number of ongoing
clinical trials. PET/CT for lymphoma restaging should also
be interpreted with some caution in the setting of HIV, as
they appear to be less speciﬁc for persistent disease than in
non-HIV-infected patients [59]. Positive PET scans should,6 Advances in Hematology
therefore, prompt tissue sampling to conﬁrm persistent or
recurrent disease prior to altering therapy for presumed
treatment failure. At present, surveillance PET/CT scans
should not be performed in routine follow-up after patients
achieve a CR, where CT scans alone remain suﬃcient.
8.ToxicityandSupportiveCare
While the use of cART in combination with full-dose
chemotherapy has resulted in improved clinical outcomes,
HIV-positive HL patients remain at signiﬁcantly increased
risk for treatment-related complications, including infec-
tions and drug toxicity. Drug interactions between antiretro-
viral medications and chemotherapy may lead to increased
levels and toxicity of some agents, while others may become
subtherapeutic[60].Numerousantiretroviraldrugs,particu-
larlythenonnucleosidereversetranscriptaseinhibitors,serve
as inducers of the cytochrome P450 (CYP450) system, while
others, especially the protease inhibitors, inhibit CYP450.
Manipulation of the CYP450 system aﬀects the metabolism
of both antiretroviral drugs and chemotherapy agents. Mul-
tiple chemotherapies, including doxorubicin, dacarbazine,
vinblastine, and etoposide, are metabolized by the CYP450
system,andassuchtheirlevelsmaybeincreasedordecreased
inthesettingofCYP450inhibitionorinduction,respectively.
This may lead to enhanced myelosuppression, as well as
increased risk of neuropathy related to increased vinblastine
levels. Stavudine and didanosine are likewise associated with
neurotoxicity and should be avoided when treating with a
vinca alkaloid or other neurotoxic chemotherapies (taxanes
and platinums). There is evidence that use of chemotherapy
and zidovudine, with its aﬀect on myelopoiesis, and/or
protease inhibitors, with their potent inhibition of CYP3A,
results in greater myelotoxicity and prolonged neutropenia;
avoidance of these drugs should be considered, if possible
[61]. The routine, prophylactic use of G-CSF and Pneumo-
cystis jiroveci prophylaxis (regardless of the CD4 count prior
to treatment) is recommended for all patients to minimize
the extent of myelosuppression and the risk of infection in
these immunosuppressed patients. Additionally, providers
should pay careful attention to pulmonary symptoms during
treatment, as the eﬀect of HIV disease and associated
opportunistic infections of the lungs may potentiate the
pulmonary toxicity of bleomycin. Caution should also be
taken in dosing of hepatically cleared chemotherapy agents
such as vinca alkaloids and doxorubicin based on bilirubin
levels. Certain protease inhibitors, most notably atazanavir
and indinavir, cause an indirect hyperbilirubinemia due
to inhibition of UGT1A1 in the liver, but this does not
aﬀect drug clearance. An indirect hyperbilirubinemia with
a normal direct bilirubin and absence of other ﬁndings of
hepatotoxicityshould,therefore,notpromptdosereductions
of chemotherapy drugs. These risks notwithstanding cART
can clearly be administered safely in combination with
chemotherapy, even with dose-intensive regimens, with
acceptabletoxicity proﬁles [32–37,62,63]. Careful attention,
however, must be paid to potential drug-drug interactions
and toxicities. Given the increased risk of toxicities due to
drug-drug interactions but the clear beneﬁt of administering
combination chemotherapy concurrently with cART, these
patients should ideally be cared for by oncologists experi-
enced in the care of HIV-associated malignancies, and their
care requires close collaboration of a multidisciplinary care
team including oncologists and infectious disease specialists.
9. Conclusions
Although the incidence of HIV-HL has not declined in the
decades since the introduction of cART, the prognosis has
signiﬁcantly improved and is now analogous to their risk-
and stage-matched HIV-negative counterparts when treated
with full-dose chemotherapy and concurrent cART. The lack
of randomized trials in this disease makes it diﬃcult to
identify an optimum regimen for the upfront treatment of
these patients, but ABVD appears to be eﬃcacious and well
tolerated, even in high-risk patients. Further study is needed
to compare treatment regimens and to validate the use of
PET/CT scans in the staging, interim restaging, and post-
treatment evaluation of HIV-HL. In addition, the promising
experience of novel therapies like brentuximab vedotin and
others will ideally be tested speciﬁcally in HIV-infected
patients.Finally,evaluationoflong-termandlate-treatment-
related toxicity is needed in patients with HIV-HL due to
the increasing success of our therapies and the encouragingly
long survivals of these patients in the modern era.
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